Yan Leyfman: Inavolisib with palbociclib–fulvestrant for PIK3CA-mutated, HR+, HER2- breast cancer
“A Phase 3 study led by Global Breast Cancer Leader Dr. Komal Jhaveri of Memorial Sloan Kettering Cancer Center showed that inavolisib, combined with palbociclib–fulvestrant, significantly improved PFS for patients with PIK3CA-mutated, HR+, HER2- advanced breast cancer, compared to standard treatment.”
“Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer”
Authors: Nicholas Turner, Seock-Ah Im, Cristina Saura, Chunyan Song, Komal Jhaveri et al.
More posts featuring Yan Leyfman.
Yan Leyfman MD, is the Co-founder and executive director of MedNews Week. He is also the Medical correspondent at OncLive. He is also the Executive Committee Member at Music Beats Cancer. He is a Clinical Researcher at Icahn School of Medicine at Mount Sinai. His research interests include oncology, Immunooncology, Cellular Therapy, and Immunotherapy.
Komal Jhaveri holds the Patricia and James Cayne Chair for Junior Faculty and serves as an Associate Member in the Breast Medicine Service and Early Drug Development at Memorial Sloan Kettering Cancer Center. As Section Head of the Endocrine Therapy Research Program and Clinical Director of the Early Drug Development Service, Dr. Jhaveri focuses on innovative approaches for breast cancer treatment, particularly in early-phase clinical trials.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023